Actively Recruiting
Evaluation of Vebreltinib Combined with Furmonertinib as First Treatment for Advanced Non-Small Cell Lung Cancer with EGFR Mutations and High PD-L1 Expression
Led by Second Affiliated Hospital of Nanchang University · Updated on 2026-06-18
45
Participants Needed
1
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining Vebreltinib with Furmonertinib as a first-line treatment for patients who have locally advanced or metastatic non-small cell lung cancer NSCLC with specific EGFR mutations and high PD-L1 expression TPS 50%. This phase IbII study addresses the challenge of primary resistance to third-generation EGFR-TKI monotherapy in this patient group. The study is designed to find an optimal dose and assess progression-free survival along with other outcomes. In the phase Ib portion, 12 to 16 patients will be enrolled to compare two doses of Vebreltinib 100mg twice daily versus 150mg twice daily, both combined with Furmonertinib 80mg once daily, to determine the recommended dose for phase II. The phase II portion will treat 37 patients, including those from the phase Ib recommended dose group, using the determined dose until disease progression, death, withdrawal, or unacceptable toxicity occurs. The phase Ib includes an initial 28-day toxicity observation period, while the phase II focuses on longer-term treatment and response. Participants will undergo imaging scans every 8 weeks to monitor tumor response, and an additional scan on day 28 of cycle 1 for phase Ib patients. Safety is closely monitored using adverse event reports, lab tests, electrocardiograms, and heart ultrasound exams. The main outcome measured is progression-free survival, with other outcomes including response rates, overall survival, and safety. Treatment continues until progression or other stopping criteria, with assessments lasting up to 24 months for progression and up to 36 months for overall survival.
CONDITIONS
Brief Title
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
Research Team
J
Jing Cai, MD, PhD
L
Liangqian Lv, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here